IN2014DN03169A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN03169A IN2014DN03169A IN3169DEN2014A IN2014DN03169A IN 2014DN03169 A IN2014DN03169 A IN 2014DN03169A IN 3169DEN2014 A IN3169DEN2014 A IN 3169DEN2014A IN 2014DN03169 A IN2014DN03169 A IN 2014DN03169A
- Authority
- IN
- India
- Prior art keywords
- pioglitazone
- salt
- average
- time point
- sustained release
- Prior art date
Links
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 6
- 229960005095 pioglitazone Drugs 0.000 abstract 3
- 239000003405 delayed action preparation Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000007922 dissolution test Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000012085 test solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011232302 | 2011-10-21 | ||
| PCT/JP2012/077662 WO2013058409A1 (en) | 2011-10-21 | 2012-10-19 | Sustained-release preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN03169A true IN2014DN03169A (OSRAM) | 2015-05-22 |
Family
ID=47178262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3169DEN2014 IN2014DN03169A (OSRAM) | 2011-10-21 | 2012-10-19 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9907789B2 (OSRAM) |
| EP (1) | EP2768487B1 (OSRAM) |
| JP (1) | JP6093762B2 (OSRAM) |
| KR (1) | KR20140081826A (OSRAM) |
| CN (1) | CN104039313A (OSRAM) |
| AP (1) | AP2014007645A0 (OSRAM) |
| AR (1) | AR088398A1 (OSRAM) |
| AU (1) | AU2012326976B2 (OSRAM) |
| BR (1) | BR112014008744A2 (OSRAM) |
| CA (1) | CA2852417A1 (OSRAM) |
| CL (1) | CL2014000992A1 (OSRAM) |
| CO (1) | CO6960544A2 (OSRAM) |
| CR (1) | CR20140213A (OSRAM) |
| DO (1) | DOP2014000077A (OSRAM) |
| EA (1) | EA201490840A1 (OSRAM) |
| EC (1) | ECSP14013328A (OSRAM) |
| IL (1) | IL232114A0 (OSRAM) |
| IN (1) | IN2014DN03169A (OSRAM) |
| MA (1) | MA35717B1 (OSRAM) |
| MX (1) | MX2014004679A (OSRAM) |
| NZ (1) | NZ624275A (OSRAM) |
| PE (1) | PE20141189A1 (OSRAM) |
| PH (1) | PH12014500856A1 (OSRAM) |
| SG (2) | SG2014012025A (OSRAM) |
| TN (1) | TN2014000152A1 (OSRAM) |
| TW (1) | TW201323018A (OSRAM) |
| UA (1) | UA113858C2 (OSRAM) |
| UY (1) | UY34403A (OSRAM) |
| WO (1) | WO2013058409A1 (OSRAM) |
| ZA (1) | ZA201403103B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2768487B1 (en) | 2011-10-21 | 2020-06-03 | Zinfandel Pharmaceuticals, Inc. | Sustained-release preparation |
| PT3070081T (pt) | 2012-04-20 | 2018-05-21 | Gilead Sciences Inc | Derivados do ácido benzotiazol-6-ilacético e sua utilização para tratar uma infeção por vih |
| US20150141517A1 (en) * | 2013-11-15 | 2015-05-21 | Shin-Etsu Chemical Co., Ltd. | Granulated composite, rapid release tablet and method for producing same |
| KR102485766B1 (ko) | 2019-12-11 | 2023-01-09 | 한국유나이티드제약 주식회사 | 생체이용률이 향상된 피오글리타존 함유 약학조성물 |
| UY39094A (es) * | 2020-02-27 | 2021-07-30 | Hk Inno N Corp | Composición farmacéutica que comprende compuesto derivado de bencimidazol |
| WO2025064867A1 (en) * | 2023-09-21 | 2025-03-27 | Yuva Biosciences, Inc. | Delivery system for mitochondrial health enhancers |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810502A (en) | 1987-02-27 | 1989-03-07 | Alza Corporation | Pseudoephedrine brompheniramine therapy |
| US4820522A (en) | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| JPH0624991A (ja) | 1991-06-20 | 1994-02-01 | Tokyo Tanabe Co Ltd | ウルソデスオキシコール酸持続性製剤 |
| JPH0624959A (ja) | 1991-10-04 | 1994-02-01 | Bayer Yakuhin Kk | 胃内浮遊型薬物徐放性固形製剤 |
| WO1994006414A1 (fr) | 1992-09-18 | 1994-03-31 | Yamanouchi Pharmaceutical Co., Ltd. | Preparation d'hydrogel a liberation prolongee |
| JPH06316517A (ja) | 1993-02-22 | 1994-11-15 | Grelan Pharmaceut Co Ltd | 放出制御製剤 |
| WO1998056359A2 (de) | 1997-06-13 | 1998-12-17 | Roland Bodmeier | Zusammensetzungen, die die wirkstofffreisetzung verzögern |
| US6191154B1 (en) | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| CA2456034A1 (en) | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
| CN101623274B (zh) | 2002-09-20 | 2012-06-27 | 华生制药公司 | 含有双胍和噻唑烷二酮衍生物的药物剂型 |
| US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| JP4493970B2 (ja) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
| IN192749B (OSRAM) | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
| US7442387B2 (en) | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
| CA2519208A1 (en) | 2003-03-17 | 2004-09-30 | Takeda Pharmaceutical Company Limited | Controlled release composition |
| JP4933033B2 (ja) | 2003-03-17 | 2012-05-16 | 武田薬品工業株式会社 | 放出制御組成物 |
| WO2004108161A1 (ja) | 2003-06-06 | 2004-12-16 | Takeda Pharmaceutical Company Limited | 固形製剤 |
| JP2005015477A (ja) | 2003-06-06 | 2005-01-20 | Takeda Chem Ind Ltd | 固形製剤 |
| US20060003002A1 (en) | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
| WO2005099760A1 (ja) | 2004-04-14 | 2005-10-27 | Takeda Pharmaceutical Company Limited | 固形製剤 |
| MX2007002375A (es) | 2004-08-31 | 2007-04-23 | Pfizer Prod Inc | Formas de dosificacion de liberacion controlada combinando liberacion inmediata y liberacion sostenida de un farmaco de baja solubilidad. |
| EA200800879A1 (ru) | 2005-09-22 | 2008-10-30 | ЭсБи ФАРМКО ПУЭРТО РИКО ИНК. | Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов |
| WO2007054976A2 (en) | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd. | Lipid based controlled release pharmaceutical composition |
| WO2007072992A2 (en) | 2005-12-22 | 2007-06-28 | Takeda Pharmaceutical Company Limited | Solid preparation containing an insulin sensitizer |
| CA2647982C (en) | 2006-03-30 | 2014-06-10 | Nippon Zoki Pharmaceutical Co., Ltd. | Solid pharmaceutical preparation containing tramadol |
| JP2009534292A (ja) | 2006-04-27 | 2009-09-24 | 武田薬品工業株式会社 | 塩酸ピオグリタゾンを有するアンジオテンシンｉｉ拮抗薬の医薬組成物 |
| PL2120878T3 (pl) | 2007-02-09 | 2015-01-30 | Alphapharm Pty Ltd | Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych |
| TW200914006A (en) * | 2007-07-12 | 2009-04-01 | Takeda Pharmaceutical | Coated preparation |
| CN101269040A (zh) | 2008-05-16 | 2008-09-24 | 北京正大绿洲医药科技有限公司 | 盐酸吡格列酮缓释滴丸及其制备方法 |
| TWI478712B (zh) * | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| CA2738930C (en) | 2008-09-30 | 2021-08-17 | The Trustees Of The University Of Pennsylvania | Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors |
| CN102548544B (zh) | 2009-10-09 | 2015-01-21 | 永进药品工业株式会社 | 同时具有速效特性和长效特性的药物组合物 |
| JP2011232302A (ja) | 2010-04-30 | 2011-11-17 | Ricoh Elemex Corp | 画像検査方法及び画像検査装置 |
| CN101884627B (zh) | 2010-07-07 | 2012-01-25 | 青岛黄海制药有限责任公司 | 盐酸吡格列酮胃内滞留缓释片及其制备方法 |
| MX339844B (es) * | 2011-01-10 | 2016-06-13 | Takeda Pharmaceuticals Co | Metodos y productos de farmaco para tratar enfermedad de alzheimer. |
| EP2768487B1 (en) | 2011-10-21 | 2020-06-03 | Zinfandel Pharmaceuticals, Inc. | Sustained-release preparation |
| KR20160056691A (ko) | 2014-11-12 | 2016-05-20 | 삼성에스디아이 주식회사 | 이차전지 |
-
2012
- 2012-10-19 EP EP12784752.3A patent/EP2768487B1/en active Active
- 2012-10-19 CN CN201280062591.4A patent/CN104039313A/zh active Pending
- 2012-10-19 CA CA2852417A patent/CA2852417A1/en not_active Abandoned
- 2012-10-19 AU AU2012326976A patent/AU2012326976B2/en not_active Ceased
- 2012-10-19 AR ARP120103908A patent/AR088398A1/es unknown
- 2012-10-19 SG SG2014012025A patent/SG2014012025A/en unknown
- 2012-10-19 IN IN3169DEN2014 patent/IN2014DN03169A/en unknown
- 2012-10-19 US US14/352,785 patent/US9907789B2/en active Active
- 2012-10-19 PH PH1/2014/500856A patent/PH12014500856A1/en unknown
- 2012-10-19 MX MX2014004679A patent/MX2014004679A/es unknown
- 2012-10-19 EA EA201490840A patent/EA201490840A1/ru unknown
- 2012-10-19 AP AP2014007645A patent/AP2014007645A0/xx unknown
- 2012-10-19 TW TW101138592A patent/TW201323018A/zh unknown
- 2012-10-19 UA UAA201405332A patent/UA113858C2/uk unknown
- 2012-10-19 NZ NZ624275A patent/NZ624275A/en not_active IP Right Cessation
- 2012-10-19 UY UY0001034403A patent/UY34403A/es not_active Application Discontinuation
- 2012-10-19 KR KR1020147010504A patent/KR20140081826A/ko not_active Ceased
- 2012-10-19 BR BR112014008744A patent/BR112014008744A2/pt not_active IP Right Cessation
- 2012-10-19 SG SG10201700121YA patent/SG10201700121YA/en unknown
- 2012-10-19 JP JP2014518853A patent/JP6093762B2/ja not_active Expired - Fee Related
- 2012-10-19 WO PCT/JP2012/077662 patent/WO2013058409A1/en active Application Filing
- 2012-10-19 PE PE2014000558A patent/PE20141189A1/es not_active Application Discontinuation
-
2014
- 2014-04-11 TN TNP2014000152A patent/TN2014000152A1/en unknown
- 2014-04-13 IL IL232114A patent/IL232114A0/en unknown
- 2014-04-15 DO DO2014000077A patent/DOP2014000077A/es unknown
- 2014-04-17 CL CL2014000992A patent/CL2014000992A1/es unknown
- 2014-04-29 EC ECSP14013328 patent/ECSP14013328A/es unknown
- 2014-04-29 ZA ZA2014/03103A patent/ZA201403103B/en unknown
- 2014-05-09 CR CR20140213A patent/CR20140213A/es unknown
- 2014-05-14 CO CO14103846A patent/CO6960544A2/es unknown
- 2014-05-15 MA MA37034A patent/MA35717B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN03169A (OSRAM) | ||
| WO2009100264A3 (en) | Oral care product and methods of use thereof | |
| EP2883932A3 (en) | Aqueous solution and method for use thereof | |
| MX369121B (es) | Formulacion farmaceutica acuosa de tapentadol para administracion oral. | |
| MX2012003296A (es) | Gotas oculares acuosas que contienen latanoprost, y metodo para inhibir la adsorcion de latanoprost a una resina. | |
| PH12013500223A1 (en) | Oral care product and methods of use and manufacture thereof | |
| EA201270741A1 (ru) | Пероральные композиции и липофильные соли метилналтрексона | |
| EA201171399A1 (ru) | Способ и композиция для улучшения всасывания лекарственных средств | |
| MY159492A (en) | Solid pharmaceutical formulation with delayed release | |
| EA201490175A1 (ru) | Составы дезоксихолевой кислоты и ее солей | |
| NZ600891A (en) | Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs | |
| ZA200904543B (en) | Salts, aqueous liquid compositions containing salts of S-(+)-abscisic acid and methods of their preparation | |
| ZA201500362B (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
| ZA201100535B (en) | Salts,aqueous liquid compositions containing salts of s-(+)-abscisic acid and methods of their preparation | |
| PH12014501981A1 (en) | Method for producing enteric alginate microcapsules via ionic gelation containing diclofenac or one of the salts thereof and multiparticled pharmaceutical composition containing them | |
| PH12014502407A1 (en) | New alfentanil composition for the treatment of acute pain | |
| WO2013105924A3 (en) | Oral care compositions | |
| MY163015A (en) | Dentifrice composition | |
| IT1399923B1 (it) | Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono | |
| WO2012064306A3 (en) | Effervescent formulations of rosuvastatin | |
| TR201005241A1 (tr) | Kontrollü salım sağlayan pregabalin solüsyon formülasyonu. | |
| WO2011121475A3 (en) | Modified release dosage form comprising desvenlafaxine or salts thereof | |
| WO2012036529A3 (en) | (s)-n,n-dimethyl-3-(naphthalen-1-yloxy)-1-phenylpropan-1-amine derivatives, pharmaceutical compositions containing the derivatives and manufacturing methods thereof | |
| TH156810A (th) | สารเตรียมชนิดปลดปล่อยแบบทยอย | |
| UA79903U (en) | pharmaceutical composition |